Endometriosis is a painful and debilitating condition that affects one in every ten women. Despite being a common health issue, there are currently limited treatment…
Adrian Limani30.03.2023
Anaveon, a clinical-stage immuno-oncology company, announced updated clinical data from the ongoing Phase I/II study of ANV419 in patients with solid tumors, as well as…
Adrian Limani27.09.2022
We are excited to welcome Phialogics as our newest portfolio company! Basel, Switzerland. 20 September 2022 - Phialogics is a preclinical stage company developing cell-type-specific…
Adrian Limani20.09.2022
InCephalo AG announces that Lauren E. Abrey, MD will join the company as Chief Medical Officer (CMO). Dr. Abrey will lead the clinical and medical…
Arianna30.06.2022
One of our portfolio companies, Anaveon AG, announces FDA Safe to proceed letter for Investigational New Drug (IND) Application for its no-alpha IL-2 agonist, ANV419…
Arianna10.06.2022
We are excited to welcome Onena Medicines as our newest portfolio company! Onena Medicines is a Swiss-Spanish biotech company emerging from the Chan Zuckerberg Biohub…
Arianna11.05.2022
Engimmune is a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, founded in August 2021 by Dr. Rodrigo Vazquez-Lombardi, Prof Sai Reddy and Dr…
Arianna03.05.2022
Cimeio therapeutics is a spin-off from the University of Basel. The scientific basis was born out of years of cutting-edge research by Professor Lukas Jeker–co-founder…
Arianna13.04.2022
2022 started off on some good notes for BaseLaunch, with two new companies (one still in stealth) joining our portfolio and another one announcing the…
Arianna28.02.2022
